Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | APAF1 | O14727 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 2/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | FNTA | P49354 | 1/20 | 0.60 |
| ▸ | FNTB | P49356 | 1/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | HTR1D | P28221 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22167145 | 0.84 | MAPT (0.67) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL29629485 | 0.83 | MEN1 (0.68) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL468399 | 0.83 | MEN1 (0.68) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL21479833 | 0.82 | MAPT (0.72) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL29407882 | 0.82 | MAPT (0.72) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL24723386 | 0.81 | PKM (0.59) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL10593441 | 0.81 | ALDH1A1 (0.71) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| Indole-3-Acetic Acid SCHEMBL7887240 | 0.81 | MEN1 (0.75) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL3448734 | 0.81 | MAPT (0.70) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| Indole-3-Acetic Acid SCHEMBL26344 | 0.81 | MEN1 (0.75) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11180474-B2 | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210292300-A1 | DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-23 | — | — | US | disclosed |
| US-20180015077-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTION | NAKAMURA, ROBERT | 2018-01-18 | — | — | US | disclosed |
| US-20180015077-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTION | NAKAMURA, ROBERT | 2018-01-18 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-7838548-B2 | Compounds and methods for treating toll-like receptor 2-related diseases and conditions | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-23 | — | — | US | disclosed |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20090186855-A1 | COMPOUNDS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR 2-RELATED DISEASES AND CONDITIONS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-23 | — | — | US | disclosed |
| US-7550501-B2 | Compounds and methods for treating toll-like receptor 2-related diseases and conditions | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-23 | — | — | US | disclosed |
| US-7517998-B2 | Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2009-04-14 | — | — | US | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| US-20070167409-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | EISAI CO., LTD. (JP) | 2007-07-19 | — | — | US | disclosed |
| US-7202234-B2 | Compounds and methods for treating Toll-like receptor 2-related diseases and conditions | EISAI CO., LTD. (JP) | 2007-04-10 | — | — | US | disclosed |
| US-7202234-B2 | Compounds and methods for treating Toll-like receptor 2-related diseases and conditions | EISAI CO., LTD. (JP) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | MAPT 4521/4885MEN1 3647/4885KMT2A 4789/4885 |
| US-20090186855-A1 | COMPOUNDS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR 2-RELATED DISEASES AND CONDITIONS | TLR2, TLR6, TLR3 | MAPT 2253/4885MEN1 4397/4885KMT2A 2393/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | MAPT 4065/4885MEN1 4867/4885KMT2A 4516/4885 |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | MAPT 4065/4885MEN1 4867/4885KMT2A 4516/4885 |
| US-20210292300-A1 | DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS | TLR9, TLR7, TLR8 | MAPT 3901/4885MEN1 2060/4885KMT2A 413/4885 |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | MAPT 3481/4885MEN1 3029/4885KMT2A 1017/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | MAPT 4775/4885MEN1 4131/4885KMT2A 3629/4885 |
| US-20070167409-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | TLR2, TLR6, TLR3 | MAPT 2253/4885MEN1 4397/4885KMT2A 2393/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | MAPT 4065/4885MEN1 4867/4885KMT2A 4516/4885 |
| US-20180015077-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTION | CD4, CCR5, MMP8 | MAPT 1713/4885MEN1 4643/4885KMT2A 2227/4885 |
| US-11180474-B2 | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors | TLR9, TLR7, TLR8 | MAPT 3903/4885MEN1 2049/4885KMT2A 413/4885 |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | MAPT 4065/4885MEN1 4867/4885KMT2A 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.